Addiction. Other psychoactive substance related disorders
Conditions
Interventions
Intervention 1: Intervention group: Quetiapine tablets at a dose of 100 mg manufactured by Tadbir Kala Jam Pharmaceutical Company, 1 tablet daily, were used for 8 weeks of intervention. Intervention 2
Sponsors
Kashan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 30 Years
Inclusion criteria
Inclusion criteria: Age 15 to 30 years Meeting the criteria for cannabis dependence according to DSM-V-TR along with the client's self-report of ongoing cannabis use
Exclusion criteria
Exclusion criteria: Illiterate people Cognitive impairment (congenital or acquired) Symptoms of psychosis Suicidal thoughts Cocaine addiction Alcohol dependence Cardiovascular disorders Recent use of over-the-counter or prescription medications that are expected to have a major interaction with Quetiapine Metabolic diseases (such as epilepsy, diabetes, and neurological diseases) Dissatisfaction Patients who are unable to perform tests due to lack of concentration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cannabis craving. Timepoint: At the beginning of the study and 8 weeks after the intervention. Method of measurement: DDQ questionnaire.;Cognitive performance of cannabis users. Timepoint: At the beginning of the study and 8 weeks after the intervention. Method of measurement: Addenbrooke's Cognitive Inventory. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMotahhare Mansoornejhad
Kashan University of Medical Sciences
Outcome results
None listed